Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer.
- Author:
Joo Won CHUNG
1
;
Moon Jae CHUNG
;
Seungmin BANG
;
Seung Woo PARK
;
Si Young SONG
;
Jae Bock CHUNG
;
Jeong Youp PARK
Author Information
- Publication Type:Original Article
- Keywords: Pancreatic neoplasms; Colorectal neoplasms; Second primary neoplasm
- MeSH: Body Mass Index; Colorectal Neoplasms*; Diabetes Mellitus; Drug Therapy; Follow-Up Studies; Humans; Incidence; Mass Screening; Neoplasms, Second Primary; Pancreatic Neoplasms*; Risk Factors; Smoke; Smoking; Survivors*
- From:Gut and Liver 2017;11(5):728-732
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: We aimed to investigate the incidence of second primary pancreatic cancer (PC) after colorectal cancer (CRC) and to identify risk factors associated with subsequent PC. METHODS: The observed incidence of a subsequent PC in patients with CRC was standardized using a population with CRC from the Korean Central Cancer Registry (KCCR). The expected incidence rate of PC was obtained by assuming that the select group experienced the same cancer incidence as the corresponding general population in the KCCR. RESULTS: The registry included 4,822 patients with CRC aged 45 to 74 years, representing 16,725.1 person-years of follow-up. Thirteen patients (0.3%) were diagnosed with a subsequent PC, and the overall age-adjusted incidence of second primary PC was 269.6 per 100,000 cases. In contrast, the overall incidence of primary PC in the general population was 18.68 per 100,000 individuals. The standardized incidence ratio of subsequent PC was 14.44, which was significantly higher in patients with CRC than in the general population. Sex, diabetes mellitus, smoking, body mass index, and a history of receiving chemotherapy as a treatment for CRC did not increase the risk of subsequent development of PC. CONCLUSIONS: The risk of a second primary PC was higher in patients with CRC. Further studies are needed to identify the risk factors and generate a screening strategy for cancer survivors.
